我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300357 我武生物

已收盘 06-12 15:00:00

{"stockData":{"symbol":"300357","market":"SZ","secType":"STK","nameCN":"我武生物","latestPrice":21.36,"timestamp":1781247792000,"preClose":21.85,"halted":0,"volume":14268521,"delay":0,"changeRate":-0.0224,"floatShares":484000000,"shares":524000000,"eps":0.8134,"marketStatus":"已收盘","change":-0.49,"latestTime":"06-12 15:00:00","open":21.48,"high":22.07,"low":20.9,"amount":308000000,"amplitude":0.0535,"askPrice":21.4,"askSize":7,"bidPrice":21.36,"bidSize":801,"shortable":0,"etf":0,"ttmEps":0.8134,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":5,"adr":0,"adjPreClose":21.85,"symbolType":"stock","openAndCloseTimeList":[[1781227800000,1781235000000],[1781240400000,1781247600000]],"highLimit":24.04,"lowLimit":19.67,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":523584000,"isCdr":false,"pbRate":4.18,"roa":"--","peRate":26.260143,"roe":"4.45%","epsLYR":0.7276,"committee":0.881593,"marketValue":11184000000,"turnoverRate":0.0295,"status":1,"floatMarketCap":10336000000},"requestUrl":"/m/hq/s/300357/wiki","defaultTab":"wiki","newsList":[{"id":"2642228866","title":"我武生物最新公告：撤回“人脐带间充质干细胞II型注射液”药物临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2642228866","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642228866?lang=zh_cn&edition=full","pubTime":"2026-06-11 17:22","pubTimestamp":1781169764,"startTime":"0","endTime":"0","summary":"我武生物公告称，公司间接控股子公司浙江我武干细胞科技有限公司撤回“人脐带间充质干细胞II型注射液”药物临床试验申请。撤回原因为需完善部分药学研究，待完善后将尽快重新提交申请。该事项预计不会对公司生产经营与当期业绩产生重大影响。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。过敏原特异性免疫治疗 ，即脱敏治疗，是世界卫生组织推荐的唯一可能影响过敏性疾病自然进程的“对因治疗”方法。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100027361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639533613","title":"股市必读：我武生物（300357）5月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2639533613","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639533613?lang=zh_cn&edition=full","pubTime":"2026-05-29 02:49","pubTimestamp":1779994149,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，我武生物报收于22.13元，下跌1.64%，换手率1.37%，成交量6.63万手，成交额1.47亿元。董秘最新回复投资者： 董秘您好！公司主要产品“畅迪”贮存条件严格且为单螨、滴剂，便利性和疗效均存在短板。当日关注点来自交易信息汇总：5月28日主力资金净流出280.75万元，游资资金净流入644.69万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900002321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638669987","title":"我武生物：屋尘螨膜剂目前处于II期临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2638669987","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638669987?lang=zh_cn&edition=full","pubTime":"2026-05-28 17:21","pubTimestamp":1779960067,"startTime":"0","endTime":"0","summary":"该产品是公司主导产品“粉尘螨滴剂”的升级产品，其给药方式为舌下含服，剂型为膜剂，膜剂具有良好的舌下吸附性、更好的给药准确性、更优良的患者用药依从性。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800030279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638475509","title":"中邮证券：给予我武生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2638475509","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638475509?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:17","pubTimestamp":1779877024,"startTime":"0","endTime":"0","summary":"中邮证券有限责任公司近期对我武生物进行研究并发布了研究报告《收入稳定增长，投资收益助力26Q1净利润高增》，给予我武生物买入评级。公司为国内变应原脱敏制剂龙头，竞争格局优异，首次覆盖，给予“买入”评级。最新盈利预测明细如下：该股最近90天内共有2家机构给出评级，买入评级1家，增持评级1家。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700038537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636015092","title":"股市必读：我武生物（300357）5月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2636015092","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636015092?lang=zh_cn&edition=full","pubTime":"2026-05-18 03:25","pubTimestamp":1779045911,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，我武生物报收于24.12元，上涨0.37%，换手率1.33%，成交量6.45万手，成交额1.56亿元。公司在国内已获批上市销售的药品包括粉尘螨滴剂、黄花蒿花粉变应原舌下滴剂、以及粉尘螨皮肤点刺诊断试剂盒等系列点刺液产品。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800001422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635970481","title":"我武生物：在变应原制品领域，公司专注国内市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2635970481","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635970481?lang=zh_cn&edition=full","pubTime":"2026-05-15 16:15","pubTimestamp":1778832915,"startTime":"0","endTime":"0","summary":"公司在国内已获批上市销售的药品包括粉尘螨滴剂、黄花蒿花粉变应原舌下滴剂、以及粉尘螨皮肤点刺诊断试剂盒等系列点刺液产品。因此，黄花蒿花粉变应原舌下滴剂与粉尘螨滴剂可以形成互补。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500028191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630133003","title":"股市必读：我武生物年报 - 第四季度单季净利润同比下降20.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630133003","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630133003?lang=zh_cn&edition=full","pubTime":"2026-04-27 09:23","pubTimestamp":1777253021,"startTime":"0","endTime":"0","summary":"来自业绩披露要点：我武生物2025年主营收入10.62亿元，同比增长14.81%；归母净利润3.81亿元，同比增长19.86%；毛利率达95.24%。股本股东变化股东户数变动截至2026年3月31日公司股东户数为3.56万户，较2025年12月31日增加6453.0户，增幅22.16%；户均持股数量由1.8万股下降至1.47万股，户均持股市值为37.8万元。2025年第四季度单季主营收入2.09亿元，同比上升7.12%；单季归母净利润3607.45万元，同比下降20.83%；单季扣非净利润3418.13万元，同比下降19.69%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700008814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630324103","title":"【机构调研记录】浙商基金调研京新药业、我武生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2630324103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630324103?lang=zh_cn&edition=full","pubTime":"2026-04-27 08:03","pubTimestamp":1777248184,"startTime":"0","endTime":"0","summary":"2）我武生物 调研纪要：公司2026年一季度营收利润增长，得益于销售管理优化与市场推广加强。浙商基金成立于2010年，截至目前，资产管理规模292.67亿元，排名105/212；资产管理规模213.59亿元，排名103/212；管理公募基金数74只，排名83/212；旗下公募基金经理14人，排名93/212。旗下最近一年表现最佳的公募基金产品为浙商智选经济动能混合A，最新单位净值为0.93，近一年增长54.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700007405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630477332","title":"【机构调研记录】恒生前海基金调研我武生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2630477332","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630477332?lang=zh_cn&edition=full","pubTime":"2026-04-27 08:02","pubTimestamp":1777248161,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月24日披露的机构调研信息，恒生前海基金近期对1家上市公司进行了调研，相关名单如下：1）我武生物 调研纪要：公司2026年一季度营收利润增长，得益于销售管理优化与市场推广加强。恒生前海基金成立于2016年，截至目前，资产管理规模236.06亿元，排名118/212；资产管理规模236.03亿元，排名99/212；管理公募基金数69只，排名90/212；旗下公募基金经理8人，排名120/212。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700007380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629142928","title":"我武生物(300357)3月31日股东户数3.56万户，较上期增加22.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629142928","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629142928?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:38","pubTimestamp":1777023537,"startTime":"0","endTime":"0","summary":"证券之星消息，近日我武生物披露，截至2026年3月31日公司股东户数为3.56万户，较12月31日增加6453.0户，增幅为22.16%。在生物制品行业个股中，我武生物股东户数低于行业平均水平，截至3月31日，生物制品行业平均股东户数为3.6万户。从股价来看，2025年12月31日至2026年3月31日，我武生物区间跌幅为9.12%，在此期间股东户数增加6453.0户，增幅为22.16%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400053371.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629108893","title":"年报一季报双超预期，我武生物上涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629108893","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629108893?lang=zh_cn&edition=full","pubTime":"2026-04-24 10:13","pubTimestamp":1776996783,"startTime":"0","endTime":"0","summary":"4月24日，我武生物开盘高开高走，截至发稿，股价上涨7.50%，报27.95元，换手率2.74%，成交额3.64亿元。消息面上，4月23日晚间，我武生物同步发布2025年年度报告与2026年第一季度报告，两份财报数据扎实。核心产品粉尘螨滴剂全年贡献营收9.90亿元，同比增长11.80%。2026年一季度，我武生物延续良好势头，实现开门红。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026042400029825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629514638","title":"图解我武生物年报：第四季度单季净利润同比下降20.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629514638","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629514638?lang=zh_cn&edition=full","pubTime":"2026-04-24 01:11","pubTimestamp":1776964264,"startTime":"0","endTime":"0","summary":"证券之星消息，我武生物2025年年报显示，当年度公司主营收入10.62亿元，同比上升14.81%；归母净利润3.81亿元，同比上升19.86%；扣非净利润3.74亿元，同比上升22.16%；其中2025年第四季度，公司单季度主营收入2.09亿元，同比上升7.12%；单季度归母净利润3607.45万元，同比下降20.83%；单季度扣非净利润3418.13万元，同比下降19.69%；负债率6.41%，投资收益272.14万元，财务费用-2284.04万元，毛利率95.24%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400002921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625919874","title":"我武生物(300357.SZ)：屋尘螨膜剂II期临床试验首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2625919874","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625919874?lang=zh_cn&edition=full","pubTime":"2026-04-08 16:27","pubTimestamp":1775636875,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 我武生物(300357.SZ)发布公告，日前，公司研发的“屋尘螨膜剂”在华中科技大学同济医学院附属同济医院完成了 “在中国成人尘螨变应性鼻炎患者中评价舌下含服‘屋尘螨膜剂’有效性和安全性的临床研究——随机、双盲、安慰剂对照的II期临床试验” 的首例受试者入组，正式进入该临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622849317","title":"3月27日我武生物涨6.38%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622849317","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622849317?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:17","pubTimestamp":1774599426,"startTime":"0","endTime":"0","summary":"证券之星消息，3月27日我武生物涨6.38%，收盘报25.5元，换手率4.14%，成交量20.06万手，成交额5.0亿元。重仓我武生物的前十大公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共14家，其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为17.21亿元，最新净值1.5812，较上一交易日下跌1.0%，近一年上涨37.26%。该公募基金现任基金经理为金笑非。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","09939","BK1515","BK1574","BK0028","159938","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618917438","title":"我武生物(300357.SZ)获得人脐带间充质干细胞II型注射液药物临床试验申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2618917438","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618917438?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:49","pubTimestamp":1773218999,"startTime":"0","endTime":"0","summary":"智通财经APP讯，我武生物 发布公告，日前，公司间接控股子公司浙江我武干细胞科技有限公司获得国家药品监督管理局发出的《受理通知书》，由浙江干细胞提交的“人脐带间充质干细胞II型注射液”药物临床试验申请已获得正式受理。截至本公告披露日，国内外尚未有治疗脓毒症和脓毒性休克的间充质干细胞药物获批上市。脓毒性休克为脓毒症合并严重的循环、细胞和代谢紊乱，其死亡风险较单纯脓毒症更高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300357","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614833482","title":"我武生物最新公告：获得狗毛皮屑点刺液药物临床试验补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2614833482","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614833482?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:06","pubTimestamp":1772183192,"startTime":"0","endTime":"0","summary":"我武生物(300357.SZ)公告称，公司提交的“狗毛皮屑点刺液”药物临床试验补充申请获得批准。该药物为治疗用生物制品，剂型为皮肤点刺试剂，用于辅助诊断与狗毛皮屑致敏相关的I型变态反应性疾病。此次批准增加两种规格，并同意按新规格进行III期临床试验。该产品有望与公司已上市产品互为补充，满足更多过敏性疾病患者的检测需求。截至本公告披露日，经查询国家药品监督管理局网站，尚未有其他企业取得该品种的药品批准文号。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700027587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603096192","title":"我武生物最新公告：取得屋尘螨膜剂I期临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2603096192","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603096192?lang=zh_cn&edition=full","pubTime":"2026-01-16 17:35","pubTimestamp":1768556128,"startTime":"0","endTime":"0","summary":"我武生物(300357.SZ)公告称，日前，公司研发的“屋尘螨膜剂”完成了一项“在中国成人尘螨变应性鼻炎患者中舌下含服‘屋尘螨膜剂’的安全性和耐受性临床研究——随机、双盲、安慰剂对照、剂量递增的I期临床试验”，并取得了I期临床试验总结报告。研究者认为，在该研究中使用的各维持剂量（150BU—2700BU）均可用于II期临床研究，将通过延长给药周期和扩大样本量进一步探索各剂量的有效性和安全性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600028899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603987386","title":"股市必读：我武生物（300357）1月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2603987386","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603987386?lang=zh_cn&edition=full","pubTime":"2026-01-16 01:38","pubTimestamp":1768498690,"startTime":"0","endTime":"0","summary":"截至2026年1月15日收盘，我武生物报收于30.89元，下跌0.58%，换手率1.16%，成交量5.61万手，成交额1.73亿元。当日关注点来自交易信息汇总：1月15日主力资金净流出2565.91万元，散户资金净流入2205.81万元。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600000713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603867782","title":"我武生物：公司研发人员可借助大语言模型检索研发信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2603867782","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603867782?lang=zh_cn&edition=full","pubTime":"2026-01-15 16:21","pubTimestamp":1768465268,"startTime":"0","endTime":"0","summary":"证券之星消息，我武生物(300357)01月15日在投资者关系平台上答复投资者关心的问题。投资者提问：公司也是积极拥抱AI前沿技术来协同研发的，请问在AI+研发、AI+医疗等方面有哪些最新进展？我武生物回复：投资者您好，公司是一家专业从事过敏性疾病诊断及治疗产品的研发、生产和销售的高科技生物制药企业。公司研发人员可以借助各类大语言模型检索相关研发信息和资料，公司药品的研发进展可以关注公司的定期报告与相关临时公告。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500023599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601510006","title":"我武生物涨6.14%，西南证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2601510006","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601510006?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:44","pubTimestamp":1767599089,"startTime":"0","endTime":"0","summary":"今日我武生物涨6.14%，收盘报30.09元。2025年10月27日，西南证券研究员杜向阳发布了对我武生物的研报《2025年三季报点评：核心产品稳健增长，在研管线持续拓展》，该研报对我武生物给出“买入”评级。研报中预计2025-2027年净利润分别为3.9亿元、4.7亿元、5.7亿元，对应动态PE分别为45倍、37倍、30倍，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中信证券的王凯旋、陈竹、韩世通。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500015778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600369","300357"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781291278408,"stockEarnings":[{"period":"1week","weight":-0.0396},{"period":"1month","weight":-0.1446},{"period":"3month","weight":-0.1527},{"period":"6month","weight":-0.2854},{"period":"1year","weight":0.0123},{"period":"ytd","weight":-0.2441}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0497},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0366},{"period":"1year","weight":0.1848},{"period":"ytd","weight":0.0158}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江我武生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"35569人(较上一季度增加22.16%)","perCapita":"13604股","listingDate":"2014-01-21","address":"浙江省湖州市德清县武康镇志远北路636号","registeredCapital":"52358万元","survey":"　　浙江我武生物科技股份有限公司的主营业务是过敏性疾病诊断及治疗产品的研发、生产和销售。公司的主要产品是粉尘螨滴剂、黄花蒿花粉变应原舌下滴剂、粉尘螨皮肤点刺诊断试剂盒、屋尘螨皮肤点刺诊断试剂盒、黄花蒿花粉变应原皮肤点刺液、白桦花粉变应原皮肤点刺液、葎草花粉变应原皮肤点刺液、悬铃木花粉变应原皮肤点刺液、德国小蠊变应原皮肤点刺液、猫毛皮屑变应原皮肤点刺液。公司被浙江省经济和信息化厅、浙江省财政厅、国家税务总局浙江省税务局于2024年12月联合认定为高新技术企业。","listedPrice":20.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"我武生物,300357,我武生物股票,我武生物股票老虎,我武生物股票老虎国际,我武生物行情,我武生物股票行情,我武生物股价,我武生物股市,我武生物股票价格,我武生物股票交易,我武生物股票购买,我武生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}